the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma

Summary

A single center, non-inferiority, two-way cohort clinical study to evaluate the efficacy and safety of pegylated recombinant human granulocyte stimulating factor injection in the mobilization of autologous hematopoietic stem cells in lymphoma.

Timeline

Start

2023-05-01

Primary completion

2025-05-01

Completion

2025-07-01

Publications

• Wang B, Cao L, Li J, Zhao Y, Li J, Wen Y, Yan P, Guo W, Bai O. Polyethylene glycol-conjugated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) primary prophylaxis significantly reduces the duration of neutropenia in non-Hodgkin's lymphoma patients treated with chemotherapy: a randomised trial (NCT05834751). Transl Cancer Res. 2025 Dec 31;14(12):8990-9001. doi: 10.21037/tcr-2025-1-2613. Epub 2025 Dec 29.

Drugs

Indications